597 related articles for article (PubMed ID: 30420324)
1. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Rovin BH; Solomons N; Pendergraft WF; Dooley MA; Tumlin J; Romero-Diaz J; Lysenko L; Navarra SV; Huizinga RB;
Kidney Int; 2019 Jan; 95(1):219-231. PubMed ID: 30420324
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH; Teng YKO; Ginzler EM; Arriens C; Caster DJ; Romero-Diaz J; Gibson K; Kaplan J; Lisk L; Navarra S; Parikh SV; Randhawa S; Solomons N; Huizinga RB
Lancet; 2021 May; 397(10289):2070-2080. PubMed ID: 33971155
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of voclosporin for the treatment of lupus nephritis.
Sin FE; Isenberg D
Expert Opin Pharmacother; 2018 Oct; 19(14):1613-1621. PubMed ID: 30207816
[TBL] [Abstract][Full Text] [Related]
4. Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Phase 3 Trial.
Rubio J; Kyttaris V
ACR Open Rheumatol; 2021 Dec; 3(12):827-831. PubMed ID: 34463434
[TBL] [Abstract][Full Text] [Related]
5. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis.
van Gelder T; Lerma E; Engelke K; Huizinga RB
Expert Rev Clin Pharmacol; 2022 May; 15(5):515-529. PubMed ID: 35763288
[TBL] [Abstract][Full Text] [Related]
6. Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis.
Arriens C; Teng YKO; Ginzler EM; Parikh SV; Askanase AD; Saxena A; Gibson K; Caster DJ; Atsumi T; Lisk L; Randhawa S; Gluck R; Solomons N; Huizinga RB
Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1399-1408. PubMed ID: 36039949
[TBL] [Abstract][Full Text] [Related]
7. Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies.
Dall'Era M; Solomons N; Federico R; Truman M
Lupus; 2019 Apr; 28(5):591-596. PubMed ID: 31066646
[TBL] [Abstract][Full Text] [Related]
8. Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis.
Mejía-Vilet JM; Romero-Díaz J
Expert Rev Clin Immunol; 2021 Sep; 17(9):937-945. PubMed ID: 34392746
[TBL] [Abstract][Full Text] [Related]
9. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
10. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
11. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of randomized controlled trials comparing the effectiveness and safety of voclosporin or tacrolimus plus mycophenolate mofetil as induction treatment for lupus nephritis.
Lee YH; Song GG
Z Rheumatol; 2023 Sep; 82(7):580-586. PubMed ID: 34545430
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P
Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801
[TBL] [Abstract][Full Text] [Related]
15. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
Liu Z; Zhang H; Liu Z; Xing C; Fu P; Ni Z; Chen J; Lin H; Liu F; He Y; He Y; Miao L; Chen N; Li Y; Gu Y; Shi W; Hu W; Liu Z; Bao H; Zeng C; Zhou M
Ann Intern Med; 2015 Jan; 162(1):18-26. PubMed ID: 25383558
[TBL] [Abstract][Full Text] [Related]
16. How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.
van Gelder T
Kidney Int; 2021 Dec; 100(6):1185-1189. PubMed ID: 34284043
[TBL] [Abstract][Full Text] [Related]
17. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study).
Rémy P; Audard V; Natella PA; Pelle G; Dussol B; Leray-Moragues H; Vigneau C; Bouachi K; Dantal J; Vrigneaud L; Karras A; Pourcine F; Gatault P; Grimbert P; Ait Sahlia N; Moktefi A; Daugas E; Rigothier C; Bastuji-Garin S; Sahali D;
Kidney Int; 2018 Dec; 94(6):1217-1226. PubMed ID: 30385039
[TBL] [Abstract][Full Text] [Related]
18. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA
N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045
[TBL] [Abstract][Full Text] [Related]
19. Rituximab use as induction therapy for lupus nephritis: a systematic review.
Stolyar L; Lahita RG; Panush RS
Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
Mendonca S; Gupta D; Ali S; Gupta P
Saudi J Kidney Dis Transpl; 2017; 28(5):1069-1077. PubMed ID: 28937065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
